Literature DB >> 21610323

Polycomb group genes are targets of aberrant DNA methylation in renal cell carcinoma.

Michele Avissar-Whiting1, Devin C Koestler, E Andres Houseman, Brock C Christensen, Karl T Kelsey, Carmen J Marsit.   

Abstract

The combined effects of genetic and epigenetic aberrations are well recognized as causal in tumorigenesis. Here, we defined profiles of DNA methylation in primary renal cell carcinomas (RCC) and assessed the association of these profiles with the expression of genes required for the establishment and maintenance of epigenetic marks. A bead-based methylation array platform was used to measure methylation of 1,413 CpG loci in ~800 cancer-associated genes and three methylation classes were derived by unsupervised clustering of tumors using recursively partitioned mixture modeling (RPMM). Quantitative RT-PCR was performed on all tumor samples to determine the expression of DNMT1, DNMT3B, VEZF1 and EZH2. Additionally, methylation at LINE-1 and AluYb8 repetitive elements was measured using bisulfite pyrosequencing. Associations between methylation class and tumor stage (p = 0.05), LINE-1 (p < 0.0001) and AluYb8 (p < 0.0001) methylation, as well as EZH2 expression (p < 0.0001) were noted following univariate analyses. A multinomial logistic regression model controlling for potential confounders revealed that AluYb8 (p < 0.003) methylation and EZH2 expression (p < 0.008) were significantly associated with methylation class membership. Because EZH2 is a member of the Polycomb repressive complex 2 (PRC2), we next analyzed the distribution of Polycomb group (PcG) targets among methylation classes derived by clustering the 1,413 array CpG loci using RPMM. PcG target genes were significantly enriched (p < 0.0001) in methylation classes with greater differential methylation between RCC and non-diseased kidney tissue. This work contributes to our understanding of how repressive marks on DNA and chromatin are dysregulated in carcinogenesis, knowledge that might aid the development of therapies or preventive strategies for human malignancies.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21610323      PMCID: PMC3230543          DOI: 10.4161/epi.6.6.16158

Source DB:  PubMed          Journal:  Epigenetics        ISSN: 1559-2294            Impact factor:   4.528


  39 in total

1.  Efficient quadratic regularization for expression arrays.

Authors:  Trevor Hastie; Robert Tibshirani
Journal:  Biostatistics       Date:  2004-07       Impact factor: 5.899

Review 2.  A review of prognostic pathologic features and algorithms for patients treated surgically for renal cell carcinoma.

Authors:  Christine M Lohse; John C Cheville
Journal:  Clin Lab Med       Date:  2005-06       Impact factor: 1.935

3.  The Polycomb group protein EZH2 directly controls DNA methylation.

Authors:  Emmanuelle Viré; Carmen Brenner; Rachel Deplus; Loïc Blanchon; Mario Fraga; Céline Didelot; Lluis Morey; Aleyde Van Eynde; David Bernard; Jean-Marie Vanderwinden; Mathieu Bollen; Manel Esteller; Luciano Di Croce; Yvan de Launoit; François Fuks
Journal:  Nature       Date:  2005-12-14       Impact factor: 49.962

Review 4.  The fundamental role of epigenetic events in cancer.

Authors:  Peter A Jones; Stephen B Baylin
Journal:  Nat Rev Genet       Date:  2002-06       Impact factor: 53.242

5.  Identification of the von Hippel-Lindau disease tumor suppressor gene.

Authors:  F Latif; K Tory; J Gnarra; M Yao; F M Duh; M L Orcutt; T Stackhouse; I Kuzmin; W Modi; L Geil
Journal:  Science       Date:  1993-05-28       Impact factor: 47.728

6.  Differentiation of lung adenocarcinoma, pleural mesothelioma, and nonmalignant pulmonary tissues using DNA methylation profiles.

Authors:  Brock C Christensen; Carmen J Marsit; E Andres Houseman; John J Godleski; Jennifer L Longacker; Shichun Zheng; Ru-Fang Yeh; Margaret R Wrensch; Joseph L Wiemels; Margaret R Karagas; Raphael Bueno; David J Sugarbaker; Heather H Nelson; John K Wiencke; Karl T Kelsey
Journal:  Cancer Res       Date:  2009-07-28       Impact factor: 12.701

7.  Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma.

Authors:  J G Herman; F Latif; Y Weng; M I Lerman; B Zbar; S Liu; D Samid; D S Duan; J R Gnarra; W M Linehan
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-11       Impact factor: 11.205

8.  Changes in DNA methylation of tandem DNA repeats are different from interspersed repeats in cancer.

Authors:  Si Ho Choi; Scott Worswick; Hyang-Min Byun; Talia Shear; John C Soussa; Erika M Wolff; Dan Douer; Guillermo Garcia-Manero; Gangning Liang; Allen S Yang
Journal:  Int J Cancer       Date:  2009-08-01       Impact factor: 7.396

9.  Mutations of the VHL tumour suppressor gene in renal carcinoma.

Authors:  J R Gnarra; K Tory; Y Weng; L Schmidt; M H Wei; H Li; F Latif; S Liu; F Chen; F M Duh
Journal:  Nat Genet       Date:  1994-05       Impact factor: 38.330

10.  Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma.

Authors:  Ignacio Varela; Patrick Tarpey; Keiran Raine; Dachuan Huang; Choon Kiat Ong; Philip Stephens; Helen Davies; David Jones; Meng-Lay Lin; Jon Teague; Graham Bignell; Adam Butler; Juok Cho; Gillian L Dalgliesh; Danushka Galappaththige; Chris Greenman; Claire Hardy; Mingming Jia; Calli Latimer; King Wai Lau; John Marshall; Stuart McLaren; Andrew Menzies; Laura Mudie; Lucy Stebbings; David A Largaespada; L F A Wessels; Stephane Richard; Richard J Kahnoski; John Anema; David A Tuveson; Pedro A Perez-Mancera; Ville Mustonen; Andrej Fischer; David J Adams; Alistair Rust; Waraporn Chan-on; Chutima Subimerb; Karl Dykema; Kyle Furge; Peter J Campbell; Bin Tean Teh; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2011-01-19       Impact factor: 49.962

View more
  17 in total

1.  Peripheral blood DNA methylation profiles are indicative of head and neck squamous cell carcinoma: an epigenome-wide association study.

Authors:  Scott M Langevin; Devin C Koestler; Brock C Christensen; Rondi A Butler; John K Wiencke; Heather H Nelson; E Andres Houseman; Carmen J Marsit; Karl T Kelsey
Journal:  Epigenetics       Date:  2012-03       Impact factor: 4.528

2.  Epigenetic silencing of Na,K-ATPase β 1 subunit gene ATP1B1 by methylation in clear cell renal cell carcinoma.

Authors:  Ponniah Selvakumar; Tori A Owens; Justin M David; Nicholas J Petrelli; Brock C Christensen; Ashakumary Lakshmikuttyamma; Ayyappan K Rajasekaran
Journal:  Epigenetics       Date:  2014-01-22       Impact factor: 4.528

3.  Does Wnt/β-catenin pathway contribute to the stability of DNMT1 expression in urological cancer cell lines?

Authors:  Nuray Varol; Ece Konac; Cenk Y Bilen
Journal:  Exp Biol Med (Maywood)       Date:  2014-10-27

4.  Incorporating DNA Methyltransferase Inhibitors (DNMTis) in the Treatment of Genitourinary Malignancies: A Systematic Review.

Authors:  Michal Chovanec; Fadi Taza; Maitri Kalra; Noah Hahn; Kenneth P Nephew; Michael J Spinella; Costantine Albany
Journal:  Target Oncol       Date:  2018-02       Impact factor: 4.493

5.  HBP1-mediated transcriptional regulation of DNA methyltransferase 1 and its impact on cell senescence.

Authors:  Kewu Pan; Yifan Chen; Mendel Roth; Weibin Wang; Shuya Wang; Amy S Yee; Xiaowei Zhang
Journal:  Mol Cell Biol       Date:  2012-12-17       Impact factor: 4.272

Review 6.  Histone deacetylase inhibitors and epigenetic modifications as a novel strategy in renal cell carcinoma.

Authors:  Swathi Ramakrishnan; Roberto Pili
Journal:  Cancer J       Date:  2013 Jul-Aug       Impact factor: 3.360

7.  Alternative Splicing of EZH2 pre-mRNA by SF3B3 Contributes to the Tumorigenic Potential of Renal Cancer.

Authors:  Ke Chen; Haibing Xiao; Jin Zeng; Gan Yu; Hui Zhou; Chunhua Huang; Weimin Yao; Wei Xiao; Junhui Hu; Wei Guan; Lily Wu; Jiaoti Huang; Qihong Huang; Hua Xu; Zhangqun Ye
Journal:  Clin Cancer Res       Date:  2016-11-22       Impact factor: 12.531

Review 8.  Functional and therapeutic significance of EZH2 in urological cancers.

Authors:  Xiaobing Liu; Qingjian Wu; Longkun Li
Journal:  Oncotarget       Date:  2017-06-06

9.  Genome methylation patterns in male breast cancer - Identification of an epitype with hypermethylation of polycomb target genes.

Authors:  Ida Johansson; Martin Lauss; Karolina Holm; Johan Staaf; Cecilia Nilsson; Marie-Louise Fjällskog; Markus Ringnér; Ingrid Hedenfalk
Journal:  Mol Oncol       Date:  2015-05-08       Impact factor: 6.603

10.  Widespread resetting of DNA methylation in glioblastoma-initiating cells suppresses malignant cellular behavior in a lineage-dependent manner.

Authors:  Stefan H Stricker; Andrew Feber; Pär G Engström; Helena Carén; Kathreena M Kurian; Yasuhiro Takashima; Colin Watts; Michael Way; Peter Dirks; Paul Bertone; Austin Smith; Stephan Beck; Steven M Pollard
Journal:  Genes Dev       Date:  2013-03-15       Impact factor: 11.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.